Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EvoGenMed

Financiado

Cerrado

Evolutionary genomics new perspectives and novel medical applications

To make for better diagnostics and safer applications of genomics we need a better understanding of our genome and how it functions. Until recently we thought we knew: intergenic sequence must be largely junk and mutations that, f... ver más

30/06/2021

UBAH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITY OF BATH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

ERC-ADG-2014: ERC Advanced Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

UBAH

2.26M€ | Lider

TRITURACIÓN Y MAQUINARIA AUX...

894.90K€ | Participante

MDC

100.00K€ | Participante

UEDIN

137.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BFU2017-89488-P ESCANEO MASIVO DE MUTACIONES EN LAS INTERFACES DE INTERACCIO... 454K€ Cerrado

WGEN MUTATION Understanding mutation using genome wide sequence based appr... 100K€ Cerrado

BFU2017-82937-P MAS ALLA DE DROSOPHILA: EL PAPEL DE LOS ELEMENTOS MOVILES EN... 211K€ Cerrado

REPEATSASMUTATORS The biological role of tandem repeats as hypervariable modul... 2M€ Cerrado

DOUBLE EXPRESS Gene expression level as a keystone to understanding gene du... 2M€ Cerrado

PRE2021-100043 Molecular basis of life and disease: evolutionary genomics 101K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2015-11-18
Fecha Fin: 2021-06-30

Líder del proyecto

UNIVERSITY OF BATH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto To make for better diagnostics and safer applications of genomics we need a better understanding of our genome and how it functions. Until recently we thought we knew: intergenic sequence must be largely junk and mutations that, for example, affect genes but not the protein (synonymous mutations) must be effectively neutral. This degenerate genome view accords with the nearly-neutral theory’s prediction that selection will be weaker when populations are small. But is this all there is to it? I shall investigate two new interrelated perspectives on genome evolution. First, I suggest that to mitigate errors, owing to our high error rates, our genome can be under stronger, not weaker, selection. Second, that errors might be a source of evolutionary novelty. Error mitigation, my team has shown, often involves selection on seemingly innocuous mutations such as synonymous changes. Remarkably, we discovered that selection to ensure error-proof splicing is possibly more prevalent on synonymous mutations when populations are small, making seemingly innocuous mutations stronger candidates for human diseases. I shall provide the first test of the new error-proofing perspective through comparative genomic analysis on synonymous site evolution. To investigate error as a source of novelty I shall consider whether expression piggy-backing (expression of a gene affecting its neighbors) forces rewiring of gene networks. Importantly, I shall translate our new understanding to enable better diagnostics and improved therapeutics. I shall develop a much-needed computer package to identify candidate disease-causing synonymous changes. In addition, knowing how synonymous sites modulate splicing will allow me to design better intronless transgenes. Transgenes must also be inserted in genomic regions immune to piggy-backing. I will examine transposable element related piggy-backing to characterize safe sites for therapeutic gene insertion and mammalian transgenesis more generally.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores